AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
OLAPARIB
8 registrations across 5 African markets— 8 active
Markets with OLAPARIB
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Lynparza 100 mg Tablets_ Tablet | 🇳🇬Nigeria | AstraZeneca Nigeria Limited | active | Oct 2030 |
| Lynparza 150mg tablets Tablet, Filmcoated | 🇿🇲Zambia | Astra Zeneca UK Limited | active | Aug 2030 |
| Lynparza 150 mg film coated tablet Film-Coated Tablet | 🇰🇪Kenya | ASTRAZENECA UK LIMITED | active | Jul 2030 |
| Lynparza 100mg Tablets Tablet, Filmcoated | 🇿🇲Zambia | Astra Zeneca UK Limited | active | Jun 2030 |
| LYNPARZA 100 MG COMPRIME PELLICULE, BOITE DE 56 | 🇨🇮Côte d'Ivoire | — | active | Feb 2030 |
| LYNPARZA 150 MG COMPRIME PELLICULE, BOITE DE 56 | 🇨🇮Côte d'Ivoire | ASTRAZENECA AB | active | — |
| Lynparza 100mg Film Coated Tablet | 🇹🇿Tanzania | AstraZeneca UK Limited | active | — |
| Lynparza 150mg Film Coated Tablet | 🇹🇿Tanzania | AstraZeneca UK Limited | active | — |
OLAPARIB in Africa — Regulatory Overview
OLAPARIB is registered across 5 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Côte d'Ivoire, Tanzania, Zambia, Kenya and 1 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 8 registrations, 8 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.